STOCK TITAN

Assembly Biosciences, Inc. - ASMB STOCK NEWS

Welcome to our dedicated page for Assembly Biosciences news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Biosciences stock.

Assembly Biosciences, Inc. (NASDAQ: ASMB) is a public clinical-stage biotechnology company dedicated to advancing innovative therapies for serious viral diseases. The company focuses on two key platform programs: the treatment of Hepatitis B virus (HBV) infection and the development of novel oral live biotherapeutics for disorders associated with the microbiome.

In the HBV program, Assembly Biosciences is pioneering a new class of oral therapeutics aimed at increasing cure rates for patients with chronic HBV. The company has developed several drug candidates that inhibit various steps in the HBV lifecycle, including novel core protein allosteric modulators (CpAMs). These small molecules target and modulate the HBV core protein, a crucial component in the virus's replication process.

The microbiome program is designed to address diseases linked to dysbiosis, an imbalance in the microbial community of the gut. Assembly Biosciences employs a robust strain identification and selection process, methods for strain isolation and growth under Good Manufacturing Practices (GMP), and a patent-pending delivery system known as GEMICEL®. This system ensures targeted delivery of live biotherapeutics to specific areas in the gastrointestinal tract.

Recent achievements for Assembly Biosciences include a long-term partnership with Gilead Sciences to accelerate the development of their antiviral pipeline. This collaboration is expected to enhance the company's financial and scientific resources, positioning them to achieve critical milestones and deliver innovative treatments to patients.

Financial results for the third quarter of 2023 highlighted the company's ongoing progress, including the advancement of multiple antiviral candidates targeting herpesviruses, HBV, and hepatitis delta virus (HDV). Assembly Biosciences also announced leadership enhancements, including the appointment of Dr. Anuj Gaggar as Chief Medical Officer.

Looking ahead, Assembly Biosciences plans to have four candidates in clinical studies by the end of 2024. These include the initiation of trials for ABI-5366, a long-acting herpes simplex virus helicase-primase inhibitor, and the development of ABI-6250, an orally bioavailable small molecule for treating chronic HDV.

For more information, visit assemblybio.com.

Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) Announces Grant of Inducement Awards to Chief Medical Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced new data from its virology portfolio at the American Association for the Study of Liver Diseases (AASLD), highlighting the potential of its preclinical IFNAR agonist program to improve tolerability and the results of vebicorvir in combination with Nrtl and AB-729 in virologically suppressed patients with hepatitis B e antigen negative chronic HBV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) has partnered with Gilead Sciences to develop treatments for herpesviruses, HBV, and HDV, with 4 candidates expected in clinical development by the end of 2024. The $100 million upfront payment and investment from Gilead extends cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
Rhea-AI Summary
ASMB: Assembly Biosciences Announces Dr. Anuj Gaggar as Chief Medical Officer, Bringing Infectious Disease Expertise to Antiviral Programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
Rhea-AI Summary
Gilead Sciences and Assembly Biosciences have entered into a 12-year partnership to develop antiviral therapies for herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). Assembly Bio will receive $100 million upfront payment, including an equity investment. Gilead may opt-in for exclusive rights to Assembly Bio's programs and could purchase up to 29.9% of Assembly Bio's voting stock. Assembly Bio may receive up to $330 million per program in potential milestones and royalties. Gilead's EPS is expected to be reduced by $0.05 - $0.07 in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.23%
Tags
partnership
-
Rhea-AI Summary
Assembly Biosciences to present preclinical and clinical data at AASLD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
Rhea-AI Summary
Assembly Biosciences selects development candidate ABI-6250 for IND-enabling studies targeting chronic hepatitis D virus (HDV) infection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
Rhea-AI Summary
Assembly Biosciences to present new data on hepatitis B and hepatitis D pipeline programs at the 2023 International HBV Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
Rhea-AI Summary
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced preclinical data on ABI-5366, a long-acting herpes simplex virus (HSV) helicase inhibitor for high-recurrence genital herpes. The data showed potent antiviral activity against both HSV-1 and HSV-2, sustained plasma concentrations, and a favorable safety profile. The company plans to enter the clinic in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
none

FAQ

What does Assembly Biosciences, Inc. specialize in?

Assembly Biosciences specializes in developing innovative therapies for serious viral diseases, focusing on HBV and microbiome-related disorders.

What are the main programs of Assembly Biosciences?

The main programs are an HBV program for treating hepatitis B virus infection and a microbiome program developing novel oral live biotherapeutics.

What is the HBV program at Assembly Biosciences?

The HBV program aims to increase cure rates for chronic HBV patients using a new class of oral therapeutics that target various steps in the HBV lifecycle.

What is the microbiome program at Assembly Biosciences?

The microbiome program focuses on developing live biotherapeutics for diseases associated with the microbiome, using a targeted delivery system called GEMICEL®.

What recent achievements has Assembly Biosciences made?

Recent achievements include a partnership with Gilead Sciences, advancements in multiple antiviral candidates, and leadership enhancements such as the appointment of Dr. Anuj Gaggar as CMO.

What are the anticipated milestones for Assembly Biosciences in 2024?

Assembly Biosciences plans to have four clinical candidates in studies, including trials for ABI-5366 for herpes and ABI-6250 for chronic HDV.

How does Assembly Biosciences' GEMICEL® delivery system work?

GEMICEL® is a patent-pending system designed to deliver live biotherapeutics to specific regions of the gastrointestinal tract effectively.

What is the significance of the partnership with Gilead Sciences?

The partnership with Gilead Sciences provides Assembly Biosciences with financial and scientific resources to accelerate their antiviral pipeline and reach critical milestones.

Who is the CEO of Assembly Biosciences?

Jason Okazaki is the CEO and President of Assembly Biosciences.

Where can I find more information about Assembly Biosciences?

More information can be found on their official website at www.assemblybio.com.

Assembly Biosciences, Inc.

Nasdaq:ASMB

ASMB Rankings

ASMB Stock Data

95.94M
6.17M
32.69%
10.61%
0.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO